Comparative Pharmacology
Head-to-head clinical analysis: METHAMPEX versus MYDAYIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHAMPEX versus MYDAYIS.
METHAMPEX vs MYDAYIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methamphetamine is a sympathomimetic amine that increases synaptic concentrations of dopamine, norepinephrine, and serotonin by promoting their release from presynaptic terminals and inhibiting their reuptake. It also inhibits monoamine oxidase, reducing neurotransmitter catabolism.
MYDAYIS is a fixed-dose combination of amphetamine and dextroamphetamine, which are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mechanism of action in ADHD is not fully elucidated, but they block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase their release into the extraneuronal space.
150 mg orally twice daily for 12 weeks; alternative: 90 mg orally twice daily if tolerability issues.
Oral, 12.5 mg or 25 mg once daily in the morning.
None Documented
None Documented
Terminal elimination half-life is approximately 9-14 hours in adults with normal renal function (mean ~12 hours). In children, half-life is shorter (~8-10 hours). Context: Steady-state is achieved within 2-3 days. Half-life may be prolonged in patients with renal impairment (up to 20-30 hours) or alkaline urine (up to 30 hours).
12 hours for d-methylphenidate; 3-4 hours for l-methylphenidate; clinical context: d-isomer provides extended coverage; l-isomer contributes minimal activity
Primarily renal excretion (≥90% as unchanged drug and metabolites); approximately 70-80% as unchanged amphetamine, 10-15% as deaminated metabolites (hippuric acid, benzoic acid). Biliary/fecal excretion is negligible (<5%). Renal clearance is pH-dependent; acidic urine increases elimination. In overdose or renal impairment, elimination half-life may prolong.
Renal (approx. 90% as unchanged drug and 10% as inactive metabolites); fecal <5%
Category C
Category C
CNS Stimulant
CNS Stimulant